FY2026 EPS Estimates for Avanos Medical Decreased by Analyst

Avanos Medical, Inc. (NYSE:AVNS) – Analysts at Zacks Research cut their FY2026 earnings estimates for shares of Avanos Medical in a research report issued on Tuesday, May 26th. Zacks Research analyst Team now expects that the company will post earnings of $1.06 per share for the year, down from their prior forecast of $1.07. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.07 per share.

Other equities research analysts have also issued reports about the stock. Weiss Ratings raised shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Wall Street Zen lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Two analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Avanos Medical Trading Up 0.5%

AVNS opened at $24.73 on Wednesday. Avanos Medical has a fifty-two week low of $9.30 and a fifty-two week high of $24.91. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -15.36 and a beta of 1.58. The company’s 50 day moving average price is $20.11 and its two-hundred day moving average price is $15.23.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The firm had revenue of $182.20 million for the quarter, compared to analyst estimates of $170.00 million. During the same period in the previous year, the firm posted $0.26 EPS. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year.

Institutional Investors Weigh In On Avanos Medical

A number of institutional investors have recently modified their holdings of AVNS. EverSource Wealth Advisors LLC lifted its position in shares of Avanos Medical by 132.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after acquiring an additional 1,423 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after acquiring an additional 2,307 shares during the period. Wexford Capital LP acquired a new position in shares of Avanos Medical during the 3rd quarter valued at $70,000. Tower Research Capital LLC TRC lifted its position in shares of Avanos Medical by 433.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after acquiring an additional 5,083 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in shares of Avanos Medical by 15.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock valued at $89,000 after acquiring an additional 846 shares during the period. 95.17% of the stock is owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.